Filing Details
- Accession Number:
- 0001562180-19-005991
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-12-10 20:04:44
- Reporting Period:
- 2019-12-09
- Accepted Time:
- 2019-12-10 20:04:44
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1597553 | Sage Therapeutics Inc. | SAGE | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1612861 | Albert Robichaud | C/O Sage Therapeutics, Inc. 215 First Street Cambridge MA 02142 | Chief Scientific Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-12-09 | 6,935 | $1.36 | 102,592 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-12-09 | 5,732 | $38.25 | 108,324 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-12-09 | 3,076 | $28.63 | 111,400 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-12-09 | 25,000 | $64.16 | 136,400 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-12-09 | 6,935 | $0.00 | 6,935 | $1.36 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-12-09 | 5,732 | $0.00 | 5,732 | $38.25 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-12-09 | 3,076 | $0.00 | 3,076 | $28.63 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2024-01-24 | No | 4 | M | Direct | |
| 32,668 | 2025-01-23 | No | 4 | M | Direct | |
| 21,924 | 2026-02-08 | No | 4 | M | Direct |
Footnotes
- This transaction was executed in multiple trades at prices ranging from $63.77 USD to $64.25 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2011 Stock Option and Incentive Plan. The option vested in full on January 1, 2018.
- The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option vested in full on January 23, 2019.
- The securities awarded on 2/08/2016 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 6,250 shares of common stock vested on the one year anniversary of the vesting start date with 18,750 shares vesting in 36 equal monthly installments thereafter.
Billionaire Hedge Funds
